Company
Headquarters: Cambridge, MA, United States
Founded: 1978
Employees: 9,610
CEO: Mr. Michel Vounatsos
$38.17 Billion
USD as of Jan. 1, 2024
Biogen Inc. is a biotechnology company specialized in the treatment of neurological diseases. It researches, develops, and markets therapies for a range of diseases including Alzheimer’s disease, hemophilia, multiple sclerosis, spinal muscular atrophy, plaque psoriasis, leukemia, rheumatoid arthritis, lymphoma, neurocognitive disorders, and pain.
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
AbbVie | $285.06 B |
Roche | $240.44 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Top 1-year algo backtest: +287.69%
$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Biogen Inc. has the following listings and related stock indices.
Stock: NASDAQ: BIIB wb_incandescent
Stock: BCBA: BIIB wb_incandescent
Stock: BMV: BIIB wb_incandescent
Stock: Bovespa: BIIB34 wb_incandescent
Stock: BVS: BIIB wb_incandescent
Stock: FSX: IDP wb_incandescent
Stock: MTA: BIIB.U wb_incandescent
Avonex, Fampyra, Plegridy, Tecfidera, Tysabri, Spinraza
Founder(s): Kenneth Murray Phillip Allen Sharp Walter Gilbert Heinz Schaller Charles Weissmann
Stelios Papadopoulos (Chairman) Michel Vounatsos (CEO)
Revenue: US$10.981 billion (2021)
Operating income: US$2.84 billion (2021)
Net income: US$1.727 billion (2021)
Total assets: US$23.877 billion (2021)
Total equity: US$10.96 billion (2021)